)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Biofrontera
Biofrontera (BFRI) investor relations material
Biofrontera Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary13 Aug, 2026
Executive summary
Achieved record Q2 and H1 2026 performance as a standalone U.S. business, with net product revenue up 32.9% year-over-year to $12.0 million in Q2 2026, driven by higher Ameluz sales and accelerated order timing due to anticipated ITC supply restrictions.
Gross margin expanded to 80% from 71% a year ago, and Adjusted EBITDA improved to near breakeven at $(0.2) million, a significant improvement from a $5.1 million loss in Q2 2025.
Strategic transaction in October 2025 with Biofrontera Group granted full U.S. rights to Ameluz and RhodoLED, reducing transfer pricing costs and improving profitability.
Operating loss narrowed to $0.5 million from $5.1 million in Q2 2025, reflecting improved gross profit and lower operating expenses.
Accelerated reorder pace and strong demand for Ameluz, with pipeline progress in new indications including sBCC and acne.
Financial highlights
Q2 2026 net product revenue was $12.0 million, up 32.9% from $9.0 million in Q2 2025; H1 2026 revenue was $22.1 million, up 25.4% year-over-year.
Gross profit margin for Q2 was 80%, up from 71% in Q2 2025; H1 gross margin was 80% versus 67% in H1 2025.
Net loss for Q2 was $0.6 million ($0.05/share), a sharp improvement from $5.3 million ($0.57/share) in Q2 2025; H1 net loss was $5.4 million, improved from $9.5 million year-over-year.
Adjusted EBITDA for Q2 was $(0.2) million, up from $(5.1) million in Q2 2025; H1 Adjusted EBITDA was $(3.7) million versus $(9.5) million last year.
Cash and equivalents at June 30, 2026, were $4.7 million, down from $6.4 million at year-end 2025.
Outlook and guidance
Expectation to achieve cash flow breakeven in 2026, supported by strong commercial execution, cost discipline, and margin improvements.
Anticipate full launch of Ameluz for superficial basal cell carcinoma in Q1 2027, pending FDA approval (PDUFA date: September 28, 2026).
Plan to file for label expansion for actinic keratosis on extremities, neck, and trunk by end of Q3 2026, with FDA approval expected in Q3 2027.
Advancing acne program toward phase III, with future growth expected through expanded indications.
No formal quantitative guidance provided.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Biofrontera
- All proposals, including director elections and plan amendments, were approved by shareholders.BFRI
AGM 2026 - Revenue and margins are rising as new indications and regulatory milestones drive future growth.BFRILytham Partners Spring 2026 Investor Conference
- Q1 2026 saw 17% revenue growth, 80% gross margin, and clinical and legal developments.BFRIQ1 2026
- Stockholders will vote on director elections, incentive plan expansion, and auditor ratification.BFRIProxy filing
- Healthcare innovators project strong growth through new indications, acquisitions, and market expansion.BFRI2nd Annual Lytham Partners Healthcare Investor Summit
- Record revenues, margin expansion, and Q4 profitability set the stage for 2026 growth.BFRIQ4 2025
- Q2 revenue up 34%, net loss narrowed, debt eliminated, and new launches support growth.BFRIQ2 2024
- Revenue up 9% to $8.6M, net loss narrowed, but liquidity and Nasdaq risks persist.BFRIQ1 2025
- Record sales and clinical milestones set the stage for margin gains and growth in 2025.BFRIQ4 2024
Next Biofrontera earnings date
Q3 202613 Nov, 2026
Biofrontera
Next Biofrontera earnings date
Q3 202613 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Biofrontera Inc. is a biopharmaceutical company based in the United States, engaged in the commercialization of pharmaceutical products designed to treat dermatological conditions. The company's focus is on photodynamic therapy (PDT) and topical antibiotics. Biofrontera's product portfolio includes Ameluz, a prescription drug for the treatment of actinic keratosis, a common precancerous skin condition, when used in combination with its BF-RhodoLED lamp. Another product, Xepi, is a topical cream approved for the treatment of impetigo, a bacterial skin infection. The company is headquartered in Woburn, Massachusetts, and its shares are listed on the Nasdaq.